Bio Path | BPTH - Operating Profit


Bio Path reported $-3.24M in Operating Profit for its fiscal quarter ending in March of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -7.77M 2.99M Jun/2023
Baxter International USD -214.2M 415.4M Dec/2025
Bio Path USD -3.24M 616K Mar/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD -7.89M 540K Sep/2025
CSL USD 2.64B 1.97B Dec/2025
Grifols EUR 411.56M 15.51M Sep/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024